Running interferon interference in treating PV/ET: meeting unmet needs

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV) and essential thrombocythemia (ET) are characterized by chronic inflammation.
• Interferons (IFNs) are cytokines with immunomodulatory and antiproliferative effects, recently gaining attention for MPN treatment.

Observation:

• The precise mechanisms by which non-targeted interferon therapy selectively targets malignant clones in MPNs remain unclear.
• Foundational questions regarding patient selection, treatment timing, and duration for interferon therapy in MPNs persist.

Findings:

• This review examines the history and current understanding of interferon treatment for PV and ET, highlighting gaps in risk assessment.
• Existing mechanistic and clinical data suggest IFNs can effectively manage these proinflammatory states, though response modifiers like molecular context are crucial.

Implications:

• Further research is needed to elucidate optimal interferon treatment strategies for MPNs, including defining treatment goals and addressing challenges.
• Understanding the molecular context is key to personalizing interferon therapy and improving outcomes for patients with PV and ET.